Maria Maccecchini PhD, Founder, President, CEO, Annovis Bio has been on the path to find a way to protect nerve cells to maintain overall health. Lead therapy ANVS401 (phase 2) is designed to treat Alzheimer's, Parkinson's and other neurodegenerative diseases by tapping into the brain's defense mechanism to get rid of toxic proteins that impair axonal transport, the body's information highway. Affecting the manufacture of amyloid, tau and alpha-synuclein, the treatment is lowering inflammation and showing statistical improvement in function. #Alzheimers #Parkinsons #axonaltransport Annovisbio.com Download the transcript here